Wall Street analysts expect that Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) will report ($0.56) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Spring Bank Pharmaceuticals’ earnings. The highest EPS estimate is ($0.52) and the lowest is ($0.63). Spring Bank Pharmaceuticals reported earnings of ($0.29) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 93.1%. The business is scheduled to report its next quarterly earnings results on Wednesday, August 7th.
On average, analysts expect that Spring Bank Pharmaceuticals will report full-year earnings of ($2.18) per share for the current year, with EPS estimates ranging from ($3.19) to ($1.83). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.99) per share, with EPS estimates ranging from ($4.07) to ($2.30). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Spring Bank Pharmaceuticals.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last issued its quarterly earnings data on Monday, April 29th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.52) by $0.20.
SBPH has been the subject of several analyst reports. Piper Jaffray Companies set a $40.00 price objective on Schlumberger and gave the company a “buy” rating in a report on Monday, July 1st. Dawson James reaffirmed a “buy” rating on shares of Spring Bank Pharmaceuticals in a report on Monday, May 13th. ValuEngine cut Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Chardan Capital set a $10.00 price target on Arcimoto and gave the stock a “buy” rating in a report on Friday, April 12th. Finally, Cantor Fitzgerald set a $9.00 price target on Evofem Biosciences and gave the stock a “buy” rating in a report on Friday, April 12th. One analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Spring Bank Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $19.30.
In other Spring Bank Pharmaceuticals news, insider Martin J. Driscoll purchased 5,000 shares of Spring Bank Pharmaceuticals stock in a transaction that occurred on Tuesday, May 21st. The stock was bought at an average price of $6.63 per share, with a total value of $33,150.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Scott Andrew Smith purchased 12,000 shares of Spring Bank Pharmaceuticals stock in a transaction that occurred on Friday, June 28th. The stock was acquired at an average cost of $4.09 per share, with a total value of $49,080.00. The disclosure for this purchase can be found here. Insiders purchased a total of 42,000 shares of company stock valued at $242,930 in the last ninety days. 15.60% of the stock is currently owned by insiders.
Institutional investors have recently made changes to their positions in the business. Rhumbline Advisers grew its holdings in shares of Spring Bank Pharmaceuticals by 65.3% during the fourth quarter. Rhumbline Advisers now owns 16,771 shares of the company’s stock worth $174,000 after purchasing an additional 6,623 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Spring Bank Pharmaceuticals by 11.8% during the fourth quarter. BlackRock Inc. now owns 675,333 shares of the company’s stock worth $7,017,000 after purchasing an additional 71,266 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Spring Bank Pharmaceuticals by 5.9% during the fourth quarter. Bank of New York Mellon Corp now owns 43,789 shares of the company’s stock worth $454,000 after purchasing an additional 2,430 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Spring Bank Pharmaceuticals by 0.9% during the fourth quarter. Northern Trust Corp now owns 171,750 shares of the company’s stock worth $1,785,000 after purchasing an additional 1,507 shares in the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Spring Bank Pharmaceuticals during the fourth quarter worth about $206,000. 42.93% of the stock is owned by institutional investors and hedge funds.
Shares of SBPH stock traded up $0.06 on Friday, hitting $5.12. The company had a trading volume of 38,500 shares, compared to its average volume of 144,839. The stock has a market capitalization of $84.19 million, a price-to-earnings ratio of -2.74 and a beta of 0.37. The company’s 50-day simple moving average is $4.68. The company has a current ratio of 12.11, a quick ratio of 12.11 and a debt-to-equity ratio of 0.06. Spring Bank Pharmaceuticals has a twelve month low of $3.58 and a twelve month high of $15.00.
Spring Bank Pharmaceuticals Company Profile
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).
Featured Article: What is the formula for calculating total return?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.